2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. NKCC

NKCC

Na-K-Cl cotransporter; Na(+)-K(+)-Cl(-) cotransporter; Na+-K+-Cl− cotransporter

NKCC

Related Products

PDF 0.15 MB

NKCC (Na-K-Cl cotransporter) is a protein that aids in the active transport of sodium, potassium, and chloride into and out of cells. There are two varieties of this membrane transport protein, NKCC1 and NKCC2, however these are encoded by two different genes (SLC12A2 and SLC12A1 respectively) and are not isoforms. Two isoforms of the NKCC1/Slc12a2 gene result from keeping (isoform 1) or skipping (isoform 2) exon 21 in the final gene product. NKCC1 is widely distributed throughout the body; it has important functions in organs that secrete fluids. NKCC2 is found specifically in the kidney, where it serves to extract sodium, potassium, and chloride from the urine so that they can be reabsorbed into the blood. NKCC proteins are membrane transport proteins that transport sodium (Na), potassium (K), and chloride (Cl) ions across the cell membrane. Because they move each solute in the same direction, NKCC proteins are considered symporters.

NKCC Related Products (32):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-17468A
    Bumetanide sodium
    		Inhibitor
    Bumetanide sodium, a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide sodium is a selective NKCC1 inhibitor, and also inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
    Bumetanide sodium
  • HY-17468S1
    Bumetanide-d5 Butyl Ester
    Bumetanide-d5 Butyl Ester is the deuterium labeled Bumetanide Butyl Ester.
    Bumetanide-d<sub>5</sub> Butyl Ester
  • HY-172816
    Carbonic anhydrase inhibitor 32
    		Agonist
    Carbonic anhydrase inhibitor 32 (compound 5B) is an orally active and selective hCA (Carbonic anhydrase ) II/VII inhibitor with the Ki values of 6.3 nM, 10.1 nM and 681 nM for hCA II, hCA VII and hCA I,respectively. Carbonic anhydrase inhibitor 32 shows neuroprotective and anticonvulsant potential by reducing mTOR activation, and raising hippocampus KCC2 levels.
    Carbonic anhydrase inhibitor 32
  • HY-115606
    ML077
    		Antagonist
    ML007 is a selective antagonist targeting the neuron-specific potassium-chloride co-transporter 2 (KCC2) with an IC50 for KCC2 is 537 nM, while its inhibitory activity on KCC1 is extremely weak (IC50 > 50 μM). ML077 inhibits the chloride ion excretion function of KCC2, increasing the intracellular chloride ion concentration, thereby enhancing the depolarization mediated by chloride ion channels. ML007 can promote glucose-stimulated insulin secretion (GSIS) without relying on KATP channels. ML007 can be used to study the functions related to pain, epilepsy, and insulin secretion.
    ML077
  • HY-178362
    CAII/VII-IN-1
    		Activator
    CAII/VII-IN-1 is an orally active hCA II (KI = 12.3 nM), and hCA VII (KI = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy.
    CAII/VII-IN-1
  • HY-167082
    AY 31906
    		Modulator
    AY 31906 is an orally active pyrimidine sulfonamide diuretic. AY 31906 exhibits potent diuretic and natriuretic activities in rats and dogs, along with relatively potassium-sparing properties. AY 31906 exhibits superior activity to Furosemide (HY-B0135). AY-31906 also has antihypertensive effects and can be used in the research of cardiovascular diseases.
    AY 31906
  • HY-119816R
    Piretanide (Standard)
    Piretanide (Standard) is the analytical standard of Piretanide. This product is intended for research and analytical applications. Piretanide is an oral active, relatively safe and effective diuretic. Piretanide has the potential for the research of congestive heart failure with a potential advantage of having potassium-sparing properties. Piretanide can also be used for the research of hypertension.
    Piretanide (Standard)
  • HY-15833R
    Chlorthalidone (Standard)
    		Inhibitor
    Chlorthalidone (Standard) is the analytical standard of Chlorthalidone. This product is intended for research and analytical applications. Chlorthalidone is a thiazide-like diuretic used to treat hypertension.
    Chlorthalidone (Standard)
  • HY-W042301R
    Xipamide (Standard)
    		Inhibitor
    Xipamide (Standard) is the analytical standard of Xipamide. This product is intended for research and analytical applications. Xipamide is a sulfonamide-based diuretic. Xipamide is an antihypertensive agent able to selectively inhibit the anion exchanger (AE).
    Xipamide (Standard)
  • HY-107321R
    Azosemide (Standard)
    		Inhibitor
    Azosemide (Standard) is the analytical standard of Azosemide. This product is intended for research and analytical applications. Azosemide, a sulfonamide loop diuretic, is a potent NKCC1 inhibitor with IC50s of 0.246 μM and 0.197 μM for hNKCC1A and NKCC1B, respectively.
    Azosemide (Standard)
  • HY-B0135AR
    Furosemide sodium (Standard)
    		Inhibitor
    Furosemide (sodium) (Standard) is the analytical standard of Furosemide (sodium). This product is intended for research and analytical applications. Furosemide sodium is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
    Furosemide sodium (Standard)
  • HY-B1363S1
    Bendroflumethiazide-d7
    		Inhibitor
    Bendroflumethiazide-d7 (Bendrofluazide-d7) is deuterium labeled Bendroflumethiazide (HY-B1363). Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus.
    Bendroflumethiazide-d<sub>7</sub>